Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.
about
Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Combined alkylation and histon ...... tumors in preclinical models.
@en
Combined alkylation and histon ...... tumors in preclinical models.
@nl
type
label
Combined alkylation and histon ...... tumors in preclinical models.
@en
Combined alkylation and histon ...... tumors in preclinical models.
@nl
prefLabel
Combined alkylation and histon ...... tumors in preclinical models.
@en
Combined alkylation and histon ...... tumors in preclinical models.
@nl
P2093
P2860
P356
P1433
P1476
Combined alkylation and histon ...... n tumors in preclinical models
@en
P2093
John A Copland
Thomas Mehrling
P2860
P304
28155-28164
P356
10.18632/ONCOTARGET.25588
P407
P577
2018-06-15T00:00:00Z